Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

Partnershipocrelizumab biosimilarOcrevusPositive

AI Analysis

Summary

Teva Pharmaceuticals and Polpharma Biologics have signed a global licensing agreement for a proposed ocrelizumab biosimilar to treat multiple sclerosis. The partnership expands Teva's biosimilar portfolio through collaboration with Polpharma Biologics.

Importance:6/10

Sentiment:

0.60

biosimilarlicensing agreementglobal dealmultiple sclerosis

Related Companies

$TEVA

Read the original article

Published by Pharmaceutical Technology on July 10, 2026 9:31 AM

Read Original